Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Dec 08, 2022 12:28pm
195 Views
Post# 35159407

RE:RE:RE:RE:More astounding results....

RE:RE:RE:RE:More astounding results....Clearly todays news is substantial & additive to all we have heard the past few weeks.
No NR on the Aware-1 abstract.
I was able to see the poster from a tweet on another site.
Posituve, but boring ( very clinical), news.
Why no NR promoting the Aware-1.?
Could be not newsworthy. Aka nothing new.
or
Could be to do with the Pfizer ownership of the Bracelet data.
The A.N. News substantiates all we know to date.
now confirmed not only 3rd party. A whole different part of the world.
SP?
many are waiting for a business development deal.
minimum when A.N. Starts phase 3, they will be paying milestone payments to Onc.
First payment at start of trial. Next when 50th patient is enrolled.
others, details never disclosed.


<< Previous
Bullboard Posts
Next >>